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Objective: In Japan, with the initiation of the lung cancer screening
program, small-sized peripheral lung cancer in which the diameter is 2 cm
or less has been increasing. The purpose of this study is to determine the
clinicopathologic behavior of small-sized lung cancer. Methods: Four hun-
dred ninety-six patients with cT1 N0, peripheral, resected non-small-cell
lung cancer, who were operated on between 1980 and 1996, were selected,
grouped by tumor diameter or histologic type, and then analyzed for
clinicopathologic behavior. On the basis of measured diameter roentgeno-
graphically, the patients were divided into two groups; group c-S with
lesions 2 cm or less in diameter and group c-L with lesions 2.1 to 3 cm in
diameter. Results: Lymph node metastasis was recognized in 18% of group
c-S, in 23% of group c-L, and in 21% for the entire clinical group. The rate
of those with the progressive state was 19% in group c-S and 26% in group
c-L. The 5-year survival was 79.5% in group c-S and 69.3% in group c-L (i.e.,
there was a significant difference between the two groups). Conclusion:
Compared with the patients with lesions 2.1 to 3 cm in diameter, the
patients with small-sized lung cancer had a milder progressive state and a
better prognosis. (J Thorac Cardiovasc Surg 1998;115:1015-20)
Recently in Japan, with the spread of mass screen-ing for lung cancer, there have been many
opportunities to resect small-sized peripheral lung
cancers with diameters of 2 cm or less. Occasionally
it is difficult to decide whether we should perform
lobectomy or add systematic lymphadenectomy in
patients with small-sized lung cancers. As these
small-sized lung cancers increase, however, it be-
comes important to consider the clinicopathologic
behavior of these tumors and to determine an
optimal treatment strategy. In our institute, patients
with lung cancer have usually been treated with
lobectomy and added systematic lymphadenectomy,
and recently we began to apply limited resection to
a few patients with small-sized lung cancer. Thus we
can reliably detect the intrathoracic pathologic
spread of these small-sized lung cancers. The pur-
pose of this study is to determine the clinicopatho-
logic behavior of small-sized lung cancer retrospec-
tively.
Patients and methods
After the introduction of chest computed tomographic
scanning for preoperative clinical staging, patients with
resected primary lung cancer treated at our institution
from January 1980 to December 1996 were the subjects of
this study. The following criteria were used. Peripheral
cT1 N0 M0 lung cancer with a maximum diameter of 3 cm
or less, measured on plain chest x-ray films or computed
tomographic scans, were the first criterion. The staging of
lung cancer was based on the TNM classification of the
Union International Cancer Conference.1 The second
criterion was that the patients had no former treatment.
The third criterion was that the histologic type be non-
small-cell lung cancer, except small-cell lung cancer or
low-grade malignant tumors. The fourth criterion was that
lobectomy had been performed with complete hilar and
mediastinal lymphadenectomy. A total of 496 patients
were selected, 255 of whom were men and 241 were
women. They ranged in age from 29 to 83 years (mean age
63 years). The selected patients were separated clinically
into two subgroups by tumor diameter; the small group
(group c-S) consisted of patients in whom the tumor
diameter measured on plain chest x-ray films or by
computed tomographic scanning was 2 cm or less, and the
large group (group c-L) consisted of patients in which the
diameter was 2.1 to 3 cm. The patients were classified into
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another two subgroups based on the resected tumor
diameter; the postoperative small group (group p-S)
consisted of patients with tumors 2 cm or less in diameter,
and the postoperative large group (group p-L) consisted
of patients with tumors 2.1 to 3 cm in diameter (Fig. 1).
Among 225 group c-S patients, 149 (66%) in whom the
resected tumor diameter was 2 cm or less were classified
as group p-S, and in 271 group c-L patients, 156 (58%) in
whom the resected tumor diameter was 2.1 to 3 cm were
classified into group p-L. Three hundred five patients
(61%) showed a match between clinical diameter and
postopertive diameter, 54 patients (11%) overestimation,
and 137 patients (28%) underestimation.
Statistical analysis was carried out using the x2 test.
Survival was calculated by the Kaplan-Meier life-table
method and compared with the generalized Wilcoxon test.
Multivariance analysis of the prognostic factors was con-
ducted by Cox’s regression model. It was performed with
SAS software (SAS Institute, Inc. Cary, N.C.).
Results
When the tumor cell cytologic findings were
judged to be class IV or V, lung cancer was diag-
nosed. In 90% of the patients, lung cancer was
diagnosed before the operation (Table I). The pos-
itive rate was 92% in group c-L and 87% in group
c-S, showing a decrease with the reduction in tumor
diameter. At our institution, to obtain tumor cells,
we first examined patients with a flexible fiberoptic
bronchoscope. If no positive tumor cells were ob-
tained, we attempted percutaneous needle biopsy.
Eighty-one percent of cases were diagnosed by
examination with fiberoptic bronchoscopy and 9%
by needle biopsy. The positive rate by needle biopsy
in group c-S was higher than that in group c-L. Thus
for small-sized lung cancer the needle biopsy exam-
ination appears to increase the positive rate.
According to the classification by pathologic stag-
ing, p stage I was 82% in group c-S and 74% in
group c-L (Table II). The rate of p stage I in group
c-S was higher than in group c-L. This tendency was
also seen in the postoperative group; p stage I was
83% in group p-S and 76% in group p-L.
Lymph node metastasis was recognized histologi-
cally in 18% of group c-S, 23% of group c-L, and 21%
of the entire clinical group, whereas intrapulmonary
metastasis was recognized in 1% of group c-S, 2% of
group c-L, and 2% of the clinical group (Table III).
Pleural dissemination or malignant effusion was rec-
ognized histologically in 1% of group c-S, 3% of group
c-L, and 2% of the clinical group. If there are certain
progressive conditions, such as lymph node metastasis,
intrapulmonary metastasis, pleural dissemination, or
malignant effusion, limited resection increases the risk
of incomplete resection. Among 225 group c-S pa-
tients, lymph node metastasis alone was recognized in
Fig. 1. Schema of clinical and postoperative groups.
Group c-S consisted of cases with a maximum tumor
diameter as measured by roentgenography or computed
tomography of 2 cm or less. Group c-L consisted of cases
with a roentgenographic tumor diameter of 2.1 to 3 cm.
Group p-S consisted of cases in which the resected
specimen diameters were 2 cm or less, and group p-L
consisted of cases in which the resected specimen diame-
ters were 2.1 to 3 cm.
Table I. Preoperative diagnosis: clinical group
Group
c-S
(N 5 225)
c-L
(N 5 271)
c-Group
(N 5 496)
Diagnosed cases 195 (87%) 250 (92%) 445 (90%)
FB 168 (75%) 232 (85%) 400 (81%)
NB 27 (12%) 18 (7%) 45 (9%)
c-S, Clinical small (roentgenographically measured tumor diameter 2 cm
or less); c-L, clinical large (roentgenographically measured tumor diame-
ter 2.1 to 3 cm); c-Group, c-S 1 c-L; FB, fiberoptic bronchoscopy; NB,
needle biopsy.
Table II. Pathologic stage according to tumor
diameter
p Stage
Group
c-S
(%)
c-L
(%)
c-Group
(%)
p-S
(%)
p-L
(%)
p-Group
(%)
I 184 (82) 201 (74) 385 (78) 164 (83) 171 (76) 339 (79)
II 16 (7) 21 (8) 37 (7) 12 (6) 21 (9) 33 (8)
IIIA 21 (10) 38 (14) 59 (12) 18 (9) 24 (13) 47 (11)
IIIB 3 (1) 10 (4) 13 (3) 3 (1) 4 (2) 7 (2)
IV 1 (0) 1 (0) 2 (0) 2 (1) 0 (0) 2 (0)
c-S, Clinical small (roentgenographically measured tumor diameter 2 cm
or less); c-L, clinical large (roentgenographically measured tumor diame-
ter 2.1 to 3 cm); c-Group, c-S 1 c-L; p-S, postoperative small (tumor
diameter of resected specimen 2 cm or less); p-L, postoperative large
(tumor diameter of resected specimen 2.1 to 3 cm); p-Group, p-S 1 p-L.
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38 patients, intrapulmonary metastasis alone in 1
patient, and malignant effusion alone in 2 patients.
Lymph node metastasis and intrapulmonary metasta-
sis were recognized concurrently in one patient, and
lymph node metastasis and malignant effusion were
found concurrently in one patient. Therefore the risk
of incomplete resection was suspected to be approxi-
mately 19% in group c-S and 26% in group c-L. The
same tendency was seen in postoperative tumor diam-
eter. The incidence rates of lymph node metastasis,
intrapulmonary metastasis, pleural dissemination, and
malignant effusion in group p-L were higher than
those in group p-S. Thus the risk of incomplete
resection in p-L was higher than that in p-S.
In the clinical group, according to the classifica-
tion of histologic types, lymph node metastasis was
recognized in 11% of squamous cell carcinoma, 22%
of adenocarcinoma, and 40% of other cell types (five
patients had large cell carcinoma and five patients
had adenosquamous cell carcinoma) (Table IV).
Intrapulmonary metastasis was recognized in only
2% of patients with adenocarcinoma, pleural dis-
semination or malignant effusion in only 3% of these
patients. The risk of incomplete resection was 11%
in squamous cell carcinoma, 24% in adenocarci-
noma, with the risk rate in adenocarcinoma signifi-
cantly higher than that in squamous cell carcinoma
(p 5 0.02).
In the other subgroups of the clinical group, rates
were the same as in the postoperative group. In the
postoperative group, lymph node metastasis was
recognized in 10% of squamous cell carcinoma, 24%
of adenocarcinoma, and 2% each of intrapulmonary
metastasis and pleural dissemination or malignant
effusion with adenocarcinoma. The risk of incom-
plete resection was 10% for squamous cell carci-
noma and 22% for adenocarcinoma.
In the subgroups classified by histologic type and
tumor size, the rate of lymph node metastasis of
adenocarcinoma was higher than that of squamous
cell carcinoma in both the clinical and the postop-
erative group (Table V). For adenocarcinoma, the
positive rate of group c-S was lower than that of
group c-L, and the positive rate of group p-S was
Table III. Pathologic confirmation according to tumor diameter
Group
c-S
(N 5 225)
c-L
(N 5 271)
c-Group
(N 5 496)
p-S
(N 5 203)
p-L
(N 5 225)
p-Group
(N 5 428)
n (1) 40 (18%) 63 (23%) 103 (21%) 34 (17%) 51 (23%) 85 (20%)
pm (1) 2 (1%) 6 (2%) 8 (2%) 3 (1%) 4 (2%) 7 (2%)
D/E (1) 3 (1%) 9 (3%) 12 (2%) 3 (1%) 4 (2%) 7 (2%)
Incomp 43 (19%) 70 (26%) 113 (23%) 37 (18%) 55 (24%) 92 (21%)
c-S, Clinical small (roentgenographically measured tumor diameter 2 cm or less); c-L, clinical large (roentgenographically measured tumor diameter 2.1 to
3 cm); c-Group, c-S 1 c-L; p-S, postoperative small (tumor size of resected specimen 2 cm or less); p-L, postoperative large (tumor size of resected specimens
2.1 to 3 cm); p-Group, p-S 1 p-L; n, lymph node metastasis; pm, intrapulmonary metastasis; D/E, dissemination or malignant effusion; Incomp, incomplete
risk rate after limited resection for cases with lymph node metastasis, pulmonary metastasis, pleural dissemination, or malignant effusion.
Table IV. Pathologic confirmation according to
histologic type
Clinical group
Others
(N 5 10)
Postoperative group
Sq. ca.
(N 5 64)
Ad. ca.
(N 5 422)
Sq. ca.
(N 5 49)
Ad. ca.
(N 5 369)
n (1) 7 (11%) 92 (22%) 4 (40%) 5 (10%) 76 (21%)
pm (1) 0 (0%) 8 (2%) 0 (0%) 0 (0%) 7 (2%)
D/E (1) 0 (0%) 12 (3%) 0 (0%) 0 (0%) 7 (2%)
Incomp. 7 (11%) 102 (24%) 4 (40%) 5 (10%) 83 (22%)
Sq. ca., Squamous cell carcinoma; Ad. ca., adenocarcinoma; Others, large
cell carcinoma 1 adenosquamous cell carcinoma; n, lymph node metasta-
sis; pm, intrapulmonary metastasis; D/E, dissemination or malignant
effusion; Incomp., incomplete risk rate after limited resection for cases with
lymph node metastasis, pulmonary metastasis, pleural dissemination, or
malignant effusion.
Table V. Lymph node metastasis according to
tumor diameter and histologic type
Clinical group
c-S
(%)
c-L
(%)
c-Group
(%)
Sq. ca. 2/28 (7) 5/36 (14) 7/64 (11)
Ad. ca. 36/193 (19) 56/229 (24) 92/422 (22)
Postoperative group
p-S
(%)
p-L
(%)
p-Group
(%)
Sq. ca. 4/27 (15) 1/22 (5) 5/49 (10)
Ad. ca. 29/171 (17) 47/198 (24) 76/369 (21)
c-S, Clinical small (roentgenographically measured tumor diameter 2 cm
or less); c-L, clinical large (roentgenographically measured tumor diame-
ter 2.1 to 3 cm); c-Group, c-S 1 c-L; p-S, postoperative small (tumor
diameter of resected specimen 2 cm or less); p-L, postoperative large
(tumor diameter of 2.1 to 3 cm); p-Group, p-S 1 p-L; Sq. ca., squamous cell
carcinoma; Ad. ca., adenocarcinoma.
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lower than that of group p-L. Rates were, however,
variable in the postoperative group, with three pos-
itive cases in group c-L showing a change in diam-
eter postoperatively. Two patients shifted to group
p-S, and one patient shifted to the more than 3 cm
in diameter group. Thus the positive rate of group
p-S was higher than that of group p-L.
In squamous cell carcinoma no intrapulmonary
metastasis, dissemination, or malignant effusion was
recognized, such that the risk rate for incomplete
resection was the same as that of lymph node
metastasis (Table VI). In every group the risk rate
for incomplete resection in adenocarcinoma was
higher than that of squamous cell carcinoma,
whereas the risk rate of squamous cell carcinoma in
group c-S was significantly lower than that of ade-
nocarcinoma in group c-L (p 5 0.03).
Postoperative survivals were calculated with the
inclusion of all deaths. The 5-year survival was
79.5% in group c-S, 69.3% in group c-L, 79.2% in
group p-S and 70.4% in group p-L (Fig. 2). The
survival curve of group c-S was significantly higher
than that of group c-L (p 5 0.02), and the survival
curve of group p-S was higher than that of group p-L
(p 5 0.04). Results of multivariative analysis of the
prognostic factors are shown in Table VII. The
existence of risk factors is significant and tumor size
is not. Excluding patients with risk factors, 5-year
survival was 79.8% in group p-L (n 5 170), 88.9% in
group p-S (n 5 166), and the survival curve of group
p-S was significantly higher than that of group p-L
(p 5 0.01).
Discussion
In 1987 the Japanese Ministry of Health and
Welfare decided to include lung cancer screening
with plain chest x-ray films and sputum cytologic
examination as one of the cancer screening pro-
grams provided by the Health and Medical Services
Law for the Aged. With the spread of this program,
identification of patients with peripheral small-sized
lung cancer with a diameter of 2 cm or less has been
increasing. However, it is not easy to diagnose these
small-sized lung cancers in the preoperative period.
In the reports by Cortese and McDougall2 and
Stringfield and coworkers,3 the cytologic positive
rate by bronchoscopy in peripheral small-sized lung
cancer was low (i.e., less than 50%). Mori and
coworkers4 reported that they detected 68% of
these cases, 66% by a fiberoptic bronchoscope and
2% by needle biopsy. In our institution we were able
to diagnose 87% of small-sized lung cancers, with
12% detected by percutaneous needle biopsy. Thus
it is useful to conduct percutaneous needle biopsy
for these small-sized lung cancers.
In all our patients with lung cancer, clinical stag-
ing was done roentgenographically, with plain chest
x-ray films and computed tomographic scanning,
before the operation. The patients with tumors
estimated to be cT1 N0 M0, stage I preoperatively
and judged pathologically to be stage I accounted
for only 78%; those estimated to be peripheral
small-sized cT1 N0 M0 preoperatively and judged
pathologically to be stage I accounted for 82%. The
major cause of changes in pathologic staging was the
existence of lymph node metastasis.
The focus of this study was cT1 N0 M0 peripheral
non-small-cell lung cancer. Lymph node metastasis
was recognized in 21% of tumors 3 cm or less on the
basis of roentgenographic size and in 20% of tumors
3 cm or less measured postoperatively. Asamura and
coworkers5 reported the lymph node metastasis rate
to be 22% in cN0 non-small-cell lung cancers 3 cm
or less, and Tateishi and coworkers6 reported the
metastasis rate to be 30% in any cN non-small-lung
cancers 3 cm or less. Therefore it was suspected that
lymph node metastasis of cT1 N0 M0, peripheral,
non-small-cell lung cancer was approximately 20%.
Comparing tumors 2 cm or less with those 2.1 to 3
cm, the metastasis rate was 20% in the former and
Table VII. Multivariate analysis of prognostic
factors
Prognostic factors Difference measured p HR 95% CI
Tumor size 2 cm or less, more
than 2 cm
0.16 1.34 0.88-2.05
Risk factors Not exist, exist ,0.01 6.73 4.46-10.15
Histologic type Others, Ad. ca.,
Sq. ca.
0.06 1.96 1.21-3.18
Risk factors, Lymph node metastasis, pulmonary metastasis, pleural dis-
semination, or malignant effusion; HR, hazard ratio; CI, confidence
interval; Ad. ca., adenocarcinoma; Sq. ca., squamous cell carcinoma.
Table VI. Risk of incomplete resection according to
tumor diameter and histologic type
Group
c-S
(%)
c-L
(%)
c-Group
(%)
p-S
(%)
p-L
(%)
p-Group
(%)
Sq. ca. 2 (7) 5 (14) 7 (11) 4 (15) 1 (5) 5 (10)
Ad. ca. 36 (20) 63 (28) 102 (22) 32 (19) 51 (26) 83 (22)
c-S, Clinical small (roentgenographically measured tumor diameter 2 cm
or less); c-L, clinical large (roentgenographically measured tumor diame-
ter 2.1 to 3 cm); c-Group, c-S 1 c-L; p-S, postoperative small (tumor
diameter of resected specimen 2 cm or less); p-L, postoperative large
(tumor diameter of resected specimen 2.1 to 3 cm); p-Group, p-S 1 p-L;
Sq. ca., squamous cell carcinoma; Ad. ca., adenocarcinoma.
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33% in the latter.5 Ishida and coworkers7 reported
that the metastasis rate was 15% for tumors 2 cm or
less and 38% for those in 2.1 to 3 cm. Among our
patients the metastasis rate was 17% or 18% for
patients with small-sized lung cancers and 23% for
those with tumors 2.1 to 3 cm, but the difference
between the two groups did not reach statistical
significance.
According to histologic type, among the patients
with any cN 3 cm or less, Asamura and coworkers5
reported the lymph node metastasis rate to be 17%
in adenocarcinoma and 14% in squamous cell car-
cinoma. In our study, among the patients with cN0 3
cm or less, the metastasis rate was 22% in adeno-
carcinoma and 11% in squamous cell carcinoma.
Among the patients with tumors 2 cm or less,
Asamura and coworkers5 reported that the metas-
tasis rate was 11% in adenocarcinoma and 6% in
squamous cell carcinoma. The corresponding rates
in our series were 17% and 15%. Thus the lymph
node metastasis rate of squamous cell carcinoma
was lower than that of adenocarcinoma.
Intrapulmonary metastasis existed in 1% to 2%,
and pleural dissemination or malignant effusion was
recognized in 1% to 3%. In those with lymph node
metastasis, pulmonary metastasis, pleural dissemi-
nation, or malignant effusion, limited resection is
not appropriate. The risk rate for incomplete resec-
tion was predicted to be 18% to 19% in small-sized
lung cancer and 21% to 23% with 2.1 to 3 cm
tumors. Furthermore, according to histologic type,
there was a low incidence of squamous cell carci-
noma.
Comparing the survival rate of the group with
tumors 2 cm or less in diameter with that of the
group whose tumors were 2.1 to 3 cm in diameter,
Asamura and coworkers5 reported that there was no
difference between the two groups in those without
lymph node metastasis. In our study, however, there
were significant differences between the two groups.
Recently, Motta8 reported in a review describing the
current state in Europe that there was a definitive
difference in postoperative survival between pT1 N0
and pT2 N0. It was therefore suspected that the
postoperative survival with small-sized lung cancer
was better than that associated with tumors 2.1 to 3
cm in diameter. There have been several re-
ports7, 9, 10 indicating that the survival of patients
with small-sized lung cancer was better than that of
those with 2.1 to 3 cm tumors. The 5-year survival of
the 84 patients with 1.1 to 2 cm diameter tumors was
74% and was thus better than that of 129 patients
with 2.1 to 3 cm cancers reported by Ishida and
coworkers.7 Read and coworkers9 reported that
among T1 N0 cases undergoing several different
operative procedures, the survival of 146 patients
with tumors 2 cm or less was significantly better than
that of 98 patients with tumors 2 cm or more.
Warren and coworkers10 reported that the survival
of patients with cancers 2 cm or less was better than
Fig. 2. Postoperative survival curve. The survival curve of group c-S was significantly higher than that of
group c-L (p 5 0.02), and the survival curve of group p-S was higher than that of group p-L (p 5 0.04).
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those with tumors 2.1 to 3 cm. Thus it is our view
that among T1 N0 cases, the survival of patients with
small-sized lung cancer (i.e., a diameter of 2 cm or
less) is better than that of other T1 N0 cases.
In conclusion, in the cT1 N0 group, non-small cell
lung cancer, lymph node metastasis was recognized
in 21% and there was a possibility of progressive
disease in 23%. With small-sized lung cancers hav-
ing a diameter of 2 cm or less, lymph node metas-
tasis was recognized in 18%, and the possibility of
progressive disease in 19%. According to histologic
findings, squamous cell carcinoma had a lower rate
of lymph node metastasis and was less often a
progressive disease than adenocarcinoma.
R E F E R E N C E S
1. Mountain CF. A new international staging system for lung
cancer. Chest 1986;89:225s-33s.
2. Cortese DA, McDougall JC. Biopsy and brushing of peripheral
lung cancer with fluoroscopic guidance. Chest 1979;75:141-5.
3. Stringfield JT, Markowitz DJ, Bentz RR, Welch MH, Weg
JG. The effect of tumor size and location on diagnosis by
fiberoptic bronchoscopy. Chest 1977;72:474-6.
4. Mori K, Yanase N, Kaneko M, Ono R, Ikeda S. Diagnosis of
peripheral lung cancer in cases of tumors 2 cm or less in size.
Chest 1989;95:304-8.
5. Asamura H, Nakayama H, Kondo H, Tsuchiya R, Shimosato
Y, Naruke T. Lymph node involvement, recurrence, and
prognosis in resected small, peripheral, non-small-cell lung
carcinomas. J Thorac Cardiovasc Surg 1996;111:1125-34.
6. Tateishi M, Fukuyama Y, Hamatake M, Kohdono S, Mitsu-
domi T, Ishida T, et al. Characteristics of non-small cell lung
cancer 3 cm or less in diameter. J Surg Oncol 1995;59:251-4.
7. Ishida T, Yano T, Maeda K, Kaneko S, Tateishi M, Sugima-
chi K. Strategy for lymphadenectomy in lung cancer three
centimeters or less in diameter. Ann Thorac Surg 1990;50:
708-13.
8. Motta G. Recent advances in lung cancer surgery in Europe.
Lung Cancer 1996;16:1-11.
9. Read RC, Yoder G, Schaeffer RC. Survival after conservative
resection for T1 N0 M0 non-small cell lung cancer. Ann
Thorac Surg 1990;49:391-400.
10. Warren WH, Faber LP. Segmentectomy versus lobectomy in
patients with stage I pulmonary carcinoma. J Thorac Cardio-
vasc Surg 1994;107:1087-94.
The Journal of Thoracic and
Cardiovascular Surgery
May 1998
1 0 2 0 Koike et al.
